Impactiviti Pharmaceuticals today announced the approval of Relativiti (aprillinate oneicus), a unique therapy for treating Attention Deficit Relational Disorder (ADRD).
ADRD is a syndrome that affects approximately 96% of all males, and is characterized by a lack of listening skills, a disinterest in spousal conversation, and an obsession with sports and beer at the expense of participating in interactive male-female relationships. The 4% not so afflicted are generally comatose at any given time.
“It’s a miracle!” proclaimed Sallie Mae Keelover, whose husband was a self-described poster child for ADRD. “He used to come home from work, sit in front of ESPN Sportscenter, and grunt unintelligible syllables in response to anything I said. I could have married a houseplant if I’d wanted that kind of response to my loving attention. Now, all I have to do is slip a few grams of Relativiti into his drink, and within minutes, he is gazing deeply into my eyes and asking about my day – he even empathizes when I tell him about the latest gossip from my girlfriends.”
Relativiti (pron. Ree-late-iv-i-tee) works by temporarily transforming testosterone to a new “hybrid hormone” called Testrogen, which enables the subject to maintain critical elements of his masculinity, while also experiencing more classic female relationship traits. As an added bonus, there is also a short-term memory loss while under the influence of Relativiti, so that subjects are not aware of the temporary shift into relational mode, thereby preserving their fragile sense of impervious manhood.
In Phase III clinical trials, 99.5% of spousal units reported immense satisfaction with the results of using Relativiti, while 0.0% of the test subjects were aware of what the heck was going on. Several spousal units dropped out due to Traumatic Stress Disorder or heart attack after seeing the drug’s effects, but these risks were deemed acceptable in light of the encouraging results produced. The Fooz and Drug Association (FDA), after a few grams of Relativiti were slipped into their drinking water during deliberations, sympathized with the plight of women everywhere and fast-tracked the drug through an unheard-of 6-hour approval process (clinical note: Relativiti has a half-life of ~7 hours). Side effects were mild and transient, including drinking ultra-light beer, reading People magazine, and having difficulty deciding which power tie to wear to work. These effects generally disappeared after engaging in activities such as firing up a loud chainsaw.
Impactiviti Pharmaceuticals has been barraged with requests for Relativiti ever since word of the approval leaked out via the newly established FDA Gossip-line blog. An emotional Steve Woodpuffin, President of Impactiviti Pharma, held a news conference during which he expressed his profound feelings for the half of the world which continually wrestles with the ravages of ADRD.
“It’s been difficult, all these years, seeing women suffer with men who, due to inbred Hormonal Imbalance Syndrome (HIS), could or would not communicate effectively. After seeing the soulful look in the eyes of our initial test subjects – their genuine interest in a non-directed conversation, their affectionate expressions of care, their readiness to drop all for the sake of helping with the dishes – we knew we were well on the way to solving one of the world’s ‘Big Ones.’ The fact that we’ll make boatloads of cash in the process has also not been lost on me,” stated Woodpuffin.
Relativiti will be available, by prescription only (or OTC, or on street corners) in three strengths – Big, Mega, and Ultra-Strength. It should be noted that use of Ultra-Strength, typically administered for truck drivers and Sumo wrestlers, may cause brief episodes of uncontrollable weeping. A new formulation, for men with sensitive skin, is also in the works.
For those spousal units who truly need to administer Relativiti “on the sly,” a special fast-dissolving powdered formulation is available for sprinkling into food or drink.